Indian Pharmaceuticals Industry Report ( http://www.bharatbook.com/Market-Research-Reports/Indian-Pharmaceuticals-Industry.html ) gives profiles of Indian Pharmaceutical Industry.
Introduction
The Indian pharmaceutical industry grew at 13% during 2003-2007, driven by rising consumption levels in the country and strong demand from export markets. In 2006-07, the Indian pharma market reached US$ 8.16 billion and is estimated to reach US$ 9.77 billion in 2007-08. At present, India’s pharmaceutical industry constitutes 1-2% of the global pharmaceutical market in value terms.
Key Findings & Highlights
- The market is estimated to register sales of US$ 743 billion in 2008 with a growth of 5-6% compared with 6-7% in 2007.
- In 2007, 71% of oncology product sales came from the US and Europe’s top five markets—France, Germany, Italy, the UK and Spain.
- The growth accelerates in the seven “pharmerging” markets of China, Brazil, Mexico,
- South Korea, India, Turkey and Russia and is expected to grow by 12–13% in 2008 to US$ 85–90 billion.
- Generic producing companies Barr, Ranbaxy, Mylan, Teva, Actavis and Dr Reddy’s Labs have become dominant as they keep launching more and more generics.
- In world rankings, the Indian pharmaceutical industry stood fourth in terms of volume and 13th in terms of value in 2006-07.
- Exports are bifurcated into exports services comprising contract manufacturing, contract research.
- India currently has more than 80 FDA-approved plants, followed by Italy (55) and China (27).
Your Questions Answered
- What is the expected growth in the seven “pharmerging” markets across the world?
- What is the % of product sales came from US & Europe’s Top five markets?
- What are the primary growth drivers in pharma industry?
- Why companies are increasingly turning to licensing?
- What are the drugs dominated domestic retail pharma market in 2007?
Contact us at:
Bharat Book Bureau
Tel: 91 22 27578668
Fax: 91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
No comments:
Post a Comment